NCT04622124View on ClinicalTrials.gov

A Safety and Tolerability Study of FCN-207 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

June 7, 2022

Conditions
Hyperuricemia
Interventions
DRUG

Placebo

DIETARY_SUPPLEMENT

fasted vs. high-fat meal

DRUG

Placebo

Trial Locations (1)

100191

Peking university Third Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Fochon Pharmaceuticals, Ltd.

INDUSTRY

NCT04622124 - A Safety and Tolerability Study of FCN-207 in Healthy Volunteers | Biotech Hunter | Biotech Hunter